Ann: AGM Presentation, page-3

Yes agree NZ Trader !!

No Brainer IMC with this morning's release and trading well below cash backing

Our Flagship Commercial Assets – Once Again Generating Revenue
o Global sales increased by 425% in FY22 to AU $765k, compared to AU $146k in
FY21
o Global sales to end October increased by 343% in the FY22 to AU$500k,
compared to AU $113k LY

Collaborations with U.S. DoD – Remain Strong
o Awarded $6.2M to Clinically Evaluate a Military Strength Dosing Regimen for
Travelan
o Contact executed with US based CRO (Pharmaron) to conduct clinical trial
o IND Submission – December 2022
o Study Initiation – Q2 2023
o Top Line Results – Q4 2023